Paul B Manning's Net Worth

$425 Million

Estimate Recalculated Feb 8, 2024 12:19AM EST

Who is Paul B Manning?

Paul B Manning has an estimated net worth of $425 Million. This is based on reported shares across multiple companies, which include Liquidia Corp, Verrica Pharmaceuticals Inc., Taysha Gene Therapies, Inc., Acumen Pharmaceuticals, Inc., AveXis, Inc., Candel Therapeutics, Inc., Dova Pharmaceuticals Inc., Pasithea Therapeutics Corp., and PERRIGO CO.

SEC CIK

Paul B Manning's CIK is 0001494695

Past Insider Trading and Trends

2018 was Paul B Manning's most active year for acquiring shares with 28 total transactions. Paul B Manning's most active month to acquire stocks was the month of May. 2018 was Paul B Manning's most active year for disposing of shares, totalling 11 transactions. Paul B Manning's most active month to dispose stocks was the month of April. 2023 saw Paul B Manning paying a total of $15,987,000.30 for 16,800,907 shares, this is the most they've acquired in one year. In 2019 Paul B Manning cashed out on 14,762,242 shares for a total of $405,961,655.00, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Liquidia Corp (LQDA) Snapshot price: $13.54

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
279.33K
$7.16
$2,000,002.80
279.33K
Dec 14
Form 4
0
0
Jun 19
Form 4
0
0
Jun 17
Form 4
435.67K
435.67K
Mar 31
Form 4
392.16K
$5.10
$1,999,995.60
392.16K
Apr 18
Form 4
0
0
Aug 20
Form 4
+36.80%
198.41K
$2.52
$500,000.76
737.65K
Apr 13
Form 4
0
0
Mar 24
Form 4
0
0
Nov 18
Form 3
0
0
No matching records found

Verrica Pharmaceuticals Inc. (VRCA) Snapshot price: $5.36

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+2.61%
200K
$5.02
$1,004,000.00
7.85M
Jul 24
Form 4
+53.57%
4.76M
$2.10
$9,999,998.40
13.65M
Jul 5
Form 4
+0.62%
50K
$9.36
$467,905.29
8.15M
Dec 2 - Dec 3
Form 4
739.83K
$14.75
$10,912,492.50
739.83K
Mar 25
Form 4
+0.25%
20K
$9.09
$181,800.00
8.1M
Aug 20
Form 4
+0.68%
10K
$8.55
$85,500.00
1.48M
Aug 18
Form 4
+0.41%
6K
$6.92
$41,520.00
1.47M
Aug 17
Form 4
+12.12%
158.5K
$6.44
$1,020,985.00
1.47M
Aug 13 - Aug 14
Form 4
+0.26%
20.89K
$14.38
$300,279.84
8.08M
Oct 8 - Oct 10
Form 4
+0.51%
47.5K
$11.17
$530,811.18
9.37M
Jan 7
Form 4
+0.76%
70.2K
$14.15
$993,021.16
9.32M
Nov 12 - Nov 13
Form 4
+3.35%
300K
$15.00
$4,500,000.00
9.25M
Jun 19
Form 4
+0.43%
33K
$15.08
$497,640.00
7.79M
Aug 10
Form 4
+33,441.77%
9.14M
9.17M
Jun 19
Form 3
0
0
No matching records found

Taysha Gene Therapies, Inc. (TSHA) Snapshot price: $1.535

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+0.61%
100K
$1.63
$163,000.00
16.57M
Nov 17
Form 4
16.47M
$0.90
$14,820,000.30
16.47M
Aug 16
Form 4
+1,054.84%
1.5M
$2.00
$3,000,000.00
1.64M
Oct 31
Form 4
0
0
Jun 17
Form 4
+4.89%
201.6K
$7.80
$1,571,809.68
4.32M
Feb 2 - Feb 3
Form 4
+6.88%
2.2K
$13.19
$29,044.38
34.2K
Nov 24
Form 4
+166.67%
20K
$12.54
$250,800.00
32K
Nov 23
Form 4
0
0
Jun 17
Form 4
12K
$20.98
$251,760.00
12K
May 14
Form 4
5.3M
5.3M
Sep 28
Form 4
0
0
Sep 23
Form 3
0
0
No matching records found

Acumen Pharmaceuticals, Inc. (ABOS) Snapshot price: $3.14

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+4,370.76%
3.92M
$16.00
4.01M
Jul 6
Form 3
0
0
No matching records found

AveXis, Inc. No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-100.00%
-1.46M
0
May 15
Form 4
+0.49%
1.11K
228.75K
Mar 13
Form 4
0
0
May 30
Form 4
-19.44%
-289.86K
$34.50
-$9,999,997.50
1.2M
Sep 13
Form 4
+685.19%
1.67M
1.91M
Feb 17
Form 4
0
0
Feb 10
Form 3
0
0
No matching records found